LMO2 is part of the LIM-only family of proteins which has four members (LMO1-4) that are implicated in a variety of cancers. LMO2 is linked to diffuse large B cell lymphoma (DLBCL) and prostate cancer (1). LMO2 protein is a nuclear marker, expressed in normal germinal-center (GC) B cells and in a subset of GC-derived B-cell lymphomas. LMO2 is also expressed in bone marrow hematopoietic precursors and endothelial cells (2). By immunohistochemistry (IHC) staining, LMO2 displays a crisp nuclear localization that allows for easier interpretation of the stain on paraffin sections in comparison to the diffuse cytoplasmic staining pattern of Human Germinal center Associated Lymphoma (HGAL) (3). LMO2 serves as one of the best prognostic markers of longer survival following immunochemotherapy for DLBCL patients. Additionally, LMO2 expression in DLBCL cells results in genomic instability, which suggests that LMO2 may affect DNA repair efficiency and potentially be exploited as a biomarker to stratify patients for therapy (4).
Want to Learn More About LMO2 Antibody? Download Our Complimentary White Paper!
1. Sewell H, et al. Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex. Sci Rep. 2014;4:3643.
2. Natkunam Y, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636-42.
3. Younes SF, et al. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. The American Journal of Surgical Pathology. 2010 Sep;34(9):1266-76.
4. Parvin S, et al. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. Cancer Cell. 2019;36(3):237-49.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.